8-Aminoquinoline Therapy for Latent Malaria

Area of Science:

• Pharmacology
• Tropical Medicine
• Drug Discovery

Background:

• 8-aminoquinolines represent a critical class of antimalarial drugs.
• Their history spans from early synthesis to modern applications, marked by significant scientific and clinical challenges.
• Key drugs include plasmochin, primaquine, and tafenoquine, each with distinct therapeutic roles and limitations.

Purpose of the Study:

• To review the technical evolution and clinical practice of 8-aminoquinoline antimalarial therapy.
• To analyze the historical development and scientific insights derived from these drugs.
• To explore strategies for overcoming the limitations of current 8-aminoquinolines, particularly hemolytic toxicity.

Main Methods:

• Historical review of scientific literature and clinical data.
• Analysis of drug development timelines and regulatory approvals.
• Examination of the biochemical basis of drug toxicity, specifically glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Main Results:

• 8-aminoquinolines have been pivotal in malaria treatment, offering cures for latent infections.
• Hemolytic crises, linked to G6PD deficiency, have been a persistent challenge since the introduction of primaquine.
• Tafenoquine, approved in 2018, offers extended prophylaxis but still carries risks for G6PD-deficient patients.

Conclusions:

• The hemolytic toxicity of 8-aminoquinolines remains a significant barrier to their widespread use.
• Despite challenges, these drugs provide essential treatment options for malaria.
• Future research should prioritize developing novel antimalarials that are safe for G6PD-deficient populations.